MARKET

ZBIO

ZBIO

Zenas BioPharma Inc.
NASDAQ
16.61
+0.20
+1.22%
Opening 10:49 01/09 EST
OPEN
16.64
PREV CLOSE
16.41
HIGH
16.98
LOW
16.23
VOLUME
110.28K
TURNOVER
--
52 WEEK HIGH
44.60
52 WEEK LOW
5.83
MARKET CAP
891.61M
P/E (TTM)
-1.3112
1D
5D
1M
3M
1Y
5Y
1D
Does Zenas BioPharma (ZBIO) Pair INDIGO Success With Manageable China-Linked Risks In Its Strategy?
Simply Wall St · 10h ago
3 Stocks with a ‘Perfect 10’ Smart Score
TipRanks · 2d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 3d ago
Zenas BioPharma Price Target Cut to $19.00/Share From $37.00 by Morgan Stanley
Dow Jones · 3d ago
Zenas BioPharma Cut to Equal-Weight From Overweight by Morgan Stanley
Dow Jones · 3d ago
Morgan Stanley Downgrades Zenas BioPharma to Equal-Weight, Lowers Price Target to $19
Benzinga · 3d ago
Evercore ISI Keeps Their Buy Rating on Zenas BioPharma, Inc. (ZBIO)
TipRanks · 3d ago
Jefferson Capital, Mobix Labs And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga · 3d ago
More
About ZBIO
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.

Webull offers Zenas BioPharma Inc. stock information, including NASDAQ: ZBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZBIO stock methods without spending real money on the virtual paper trading platform.